List of Small Molecule Pharmaceuticals Companies in Louisiana - 3

Cell Line Production

Revolo Biotherapeutics is developing revolutionary therapies powered to reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases. Its two drug candidates, ‘1805 and ‘1104, a protein and a peptide respectively, reset the immune system by preventing the chronic pro-inflammatory immune response that results in autoimmune or allergic disease. ‘1805 is a modified analogue of a key molecule in immune function and is in clinical development for moderate-to-severe rheumatoid arthritis and non-infectious uveitis. ‘1104 is a peptide derived from a natural immune-regulatory protein and is in clinical development for patients with eosinophilic esophagitis (EoE) and allergic disease. The disease-agnostic mechanism of action of Revolo Biotherapeutic’s assets provides a potential platform for the development of treatments for multiple autoimmune and allergic diseases.

South Rampart Pharma, Inc. is a clinical-stage biotech company focused on addressing the critical need for a safe and effective approach to relieving pain. Its lead clinical candidate, SRP-001, is a novel, first-in-class analgesic that activates pain signaling pathways in the midbrain's periaqueductal grey (PAG) region. SRP-001 influences pain-related genes through endocannabinoid, mechanical nociception, and fatty acid amide hydrolase pathways in the PAG region. Unlike opioids, SRP-001 doesn't carry a risk of abuse and addiction. Moreover, it lacks the hepatotoxicity associated with acetaminophen as it does not produce the harmful metabolite NAPQI nor disrupt liver cell tight junctions. Compared with acetaminophen, SRP-001 exhibits similar analgesic properties without the risk of liver damage, and it lacks NSAIDs’ kidney toxicity risk. SRP-001 is effective in different pain models, including the inflammatory von Frey, visceral, and somatic pain models. Interim results from the ongoing Phase 1 trials (NCT05484414) demonstrate SRP-001's safety, tolerability, and favorable pharmacokinetics. SRP-001 represents a promising alternative to existing pain medicines like acetaminophen, NSAIDs, and opioids, potentially providing a safer, more effective pain treatment option.